Jazz Pharmaceuticals plc and Redx Pharma plc have signed a definitive agreement under which Jazz will acquire Redx’s KRAS (Kirsten rat sarcoma virus) inhibitor program.   Jazz and Redx will collaborate to advance candidates through IND-enabling studies, and Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.   “KRAS is a well-validated oncology target and there remains a high unmet need for innovation in this area bas...